Premium
Qlaira: first COC licensed for heavy menstrual bleeding
Author(s) -
Chaplin Steve,
Briggs Paula
Publication year - 2011
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.837
Subject(s) - dienogest , medicine , menstrual bleeding , estradiol valerate , gynecology , adverse effect , oral contraception , family planning , research methodology , population , endometriosis , estrogen , environmental health
Qlaira (estradiol valerate plus dienogest) is the first combined oral contraceptive to gain a licence for the treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Dr Paula Briggs discusses its place in the treatment of heavy menstrual bleeding. Copyright © 2011 Wiley Interface Ltd